Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
← catalyst calendarSponsored by Traws Pharma, Inc. (industry) · TRAW — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
15
Countries
Australia, South Korea, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-16 | actual | When the study began enrolling |
| Primary completion | Feb 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID - 19
Interventions
- Drug: Ratutrelvir (83-0060) non-randomised
- Drug: Paxlovid
- Drug: Ratutrelvir (83-0060)
Primary outcomes
what the primary-completion date above is the date OFSafety based on adverse events incidence
measured 28 days
Safety based on adverse events severity
measured 28 days
Permalink · TRAW's whole pipeline · Catalyst calendar · Every registered study · What changed